Novartis CEO Vas Narasimhan has joined the board of AI company Anthropic, appointed by the organization's Long-Term Benefit Trust. The move signals a continued focus on responsible AI development, particularly in high-stakes sectors.
Narasimhan, a physician-scientist, leads one of the world's largest pharmaceutical companies. He shares Anthropic's view that AI holds immense potential for improving human life, especially in healthcare and life sciences. This appointment underscores the growing intersection between advanced AI and the medical field.
Daniela Amodei, Anthropic’s President, highlighted Narasimhan's unique experience. "He's overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries," she stated. This background is directly relevant to Anthropic's goal of safely deploying powerful AI systems.
The Anthropic Long-Term Benefit Trust plays a crucial role in the company's governance. It ensures a balance between financial success and Anthropic's public benefit mission. The Trust's members have no financial stake in the company, aiming for objective oversight. With Narasimhan's addition, Trust-appointed directors now form a majority on the board, strengthening its commitment to responsible AI development. This strategic governance aligns with Anthropic’s safety-first strategy.
Narasimhan's career has focused on translating scientific breakthroughs into tangible benefits. His early work on HIV/AIDS, malaria, and tuberculosis programs in underserved regions demonstrates a commitment to global health equity. His appointment comes as AI continues to revolutionize AI in healthcare and life sciences.